drugset / Trial / NCT01506947
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.
Timeline
- Start
- 2012-05-10
- Primary completion
- 2016-04-07
- Completion
- 2016-04-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paricalcitol | Other / unclassified | — | Intravenous |
| Background | Darbepoetin alfa | Protein / enzyme biologic | 0.13 ug/kg | — |
| Background | Darbepoetin alfa | Protein / enzyme biologic | 0.35 ug/kg | — |